Modera Wealth Management LLC Raises Stake in AbbVie Inc. $ABBV

Modera Wealth Management LLC boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 1.5% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 76,027 shares of the company’s stock after purchasing an additional 1,088 shares during the quarter. Modera Wealth Management LLC’s holdings in AbbVie were worth $14,112,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Conning Inc. increased its holdings in AbbVie by 7.1% during the second quarter. Conning Inc. now owns 191,023 shares of the company’s stock valued at $35,458,000 after buying an additional 12,690 shares during the last quarter. Dohj LLC increased its stake in shares of AbbVie by 41.8% in the 2nd quarter. Dohj LLC now owns 4,529 shares of the company’s stock worth $802,000 after purchasing an additional 1,335 shares in the last quarter. First Hawaiian Bank raised its holdings in AbbVie by 0.8% in the 2nd quarter. First Hawaiian Bank now owns 7,556 shares of the company’s stock worth $1,403,000 after purchasing an additional 60 shares during the period. Narus Financial Partners LLC grew its holdings in AbbVie by 25.3% during the first quarter. Narus Financial Partners LLC now owns 1,988 shares of the company’s stock valued at $417,000 after purchasing an additional 401 shares during the period. Finally, BankPlus Trust Department increased its position in AbbVie by 3.3% in the second quarter. BankPlus Trust Department now owns 27,113 shares of the company’s stock worth $5,033,000 after buying an additional 855 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at AbbVie

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the transaction, the executive vice president owned 177,292 shares of the company’s stock, valued at approximately $35,178,278.64. This represents a 19.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.25% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Bank of America raised their target price on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Wall Street Zen raised AbbVie from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Guggenheim increased their target price on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Finally, Wells Fargo & Company boosted their price target on AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $238.05.

AbbVie Stock Up 1.1%

Shares of NYSE:ABBV opened at $219.13 on Friday. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61. The business has a 50 day simple moving average of $223.06 and a two-hundred day simple moving average of $201.96. AbbVie Inc. has a 1 year low of $163.81 and a 1 year high of $244.81. The firm has a market capitalization of $387.11 billion, a PE ratio of 104.35, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same period in the previous year, the firm earned $3.00 earnings per share. The business’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. AbbVie’s dividend payout ratio is presently 524.24%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.